TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06634186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The aim of the dietary intervention is the implementation of a fiber-enriched diet. Therefore, patients receive dietary counseling, supplemented with propionate, that functions as fiber-surrogate.
Study: NCT04887155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Group-based transdiagnostic cognitive-behavioral treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Group-based transdiagnostic cognitive-behavioral treatment
Study: NCT05434637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Individuals randomized to this intervention will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound-based Therapy
Description: Individuals randomized to this intervention will receive sound-based therapy, consistent with an audiology-based standard of care treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Individuals randomized to this intervention will receive both individualized physical therapy and sound-based therapy.
Study: NCT05307510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefabricated splint
Description: Subjects will be provided either a prefabricated splint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Orthosis
Description: Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
Study: NCT06633341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5 CAR T-cells
Description: Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion
Study: NCT06273267

Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).
Study: NCT05742763

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen and PRP
Description: The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen and PRP
Description: The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and PRP
Description: The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
Study: NCT05470283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBX-115
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given by IV
Study: NCT05730751

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: spinal anesthesia
Study: NCT05855122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
Study: NCT06000774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Ketogenic Diet
Description: therapeutic ketogenic diet
Study: NCT06359288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group receiving QR code supported training
Description: During the training process, QR codes were integrated into the sections related to the care of the newborn in the guide to provide mothers with the opportunity to watch the video simultaneously while reading the guide in practices requiring skills related to hygienic care of the newborn and nutrition / communication / sleep, and to allow them to watch it repeatedly as long as they feel the need. In these videos, the application steps were shown one by one. When the code is scanned with a smartphone, it automatically redirects the user to the specified URL. The QR codes in the Implementation Guide on the Care of the Newborn consist of eight videos) that allow mothers to watch the hygienic care of the newborn in practice. After the end of this phase of the training, the questionnaires were re-administered to the mothers in both groups one month after discharge.
Study: NCT06259188

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Training Device
Description: In the both groups the initial pressure load will be set to the resistance level corresponding to the 40% of the MIP and MEP measurement. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. In breathing exercise device group participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. In IMT+EMT group, patients will be able to practice different to device. As the progression progresses, the perceived exertion level will be increased by 5-10% every week, to be in the range of 4-6 according to the Modified Borg scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Breathing Exercise Device
Description: Personalized Breathing Exercise Device
Study: NCT05110482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon
Description: uterotonic drugs
Study: NCT05110482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: uterotonic drug
Study: NCT05730751

Intervention type: PROCEDURE
Intervention: caesarean section
Description: LSCS

Intervention type: PROCEDURE
Intervention: caesarean section
Description: LSCS
Study: NCT04941183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTR-441
Description: NTR-441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05229380

Intervention type: DRUG
Intervention: Saccharin test
Description: Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.

Intervention type: DRUG
Intervention: Saccharin test
Description: Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
Study: NCT05369728

Intervention type: OTHER
Group type: OTHER
Intervention: Coronary CT in 1st line compared to the strategy with functional test in 1st line in patient at Intermediate Risk of Developing Stable Coronary Disease:
Description: Coronary CT in 1st line compared to the strategy with functional test in 1st line in Patients at Intermediate Risk of Developing Stable Coronary Disease:

Intervention type: OTHER
Group type: OTHER
Intervention: Coronary CT in 1st line compared to the strategy with functional test in 1st line in patient at Intermediate Risk of Developing Stable Coronary Disease:
Description: Coronary CT in 1st line compared to the strategy with functional test in 1st line in Patients at Intermediate Risk of Developing Stable Coronary Disease:
Study: NCT05399056

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic Peer Coaching
Description: Telephonic Peer Coaching from an individual with lived experience with COPD and Pulmonary Rehabilitation trained in motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling
Description: Video narratives of an individual with lived experience with COPD and Pulmonary Rehabilitation describing their journey through Pulmonary Rehabilitation
Study: NCT05080036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medio-lateral imbalance
Description: Thrust on the pelvis in the medio-lateral direction in order to create a balance perturbation
Study: NCT05609734

Intervention type: OTHER
Intervention: no intervention, only observational retrospective study
Description: no intervention, only observational retrospective study

Intervention type: OTHER
Intervention: no intervention, only observational retrospective study
Description: no intervention, only observational retrospective study
Study: NCT05180201

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactiplantibacillus plantarum ATCC 202195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactiplantibacillus plantarum ATCC 202195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT04918589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 40 mL topical of 0.9% normal saline
Study: NCT05623618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE labelling
Description: PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
Study: NCT06045858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation Agents
Description: anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
Study: NCT04924257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Description: Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS \<10).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS \<10).
Study: NCT06045858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Agents
Description: anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
Study: NCT05390905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 Injection
Description: 1μg/kg/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: 50mg/dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05879705

Intervention type: OTHER
Group type: OTHER
Intervention: Parent intervention
Description: Family centered, strength-based, Occupational therapy intervention program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent intervention
Description: Family centered, strength-based, Occupational therapy intervention program
Study: NCT05925699

Intervention type: OTHER
Intervention: Collection of clinical, radiological, and biological data from patients' medical records
Description: Collection of clinical, radiological, and biological data from patients' medical records
Study: NCT05375656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-over study
Description: Traditional Inuit Diet and Western Diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-over study
Description: Traditional Inuit Diet and Western Diet.
Study: NCT05487976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human activated coagulation factor VII for injection
Description: Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
Study: NCT05962645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir
Description: This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir
Description: This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
Study: NCT06166342

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: Consume 1 sachet daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI153 probiotic sachet
Description: Consume 1 sachet daily
Study: NCT05871723

Intervention type: OTHER
Intervention: Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound
Description: o measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.

Intervention type: OTHER
Intervention: Berg Balance Scale
Description: The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56. The Berg Balance Scale is commonly used in clinical and research settings to assess balance impairment and monitor changes in balance over time, particularly in individuals with neurological conditions such as stroke. The test has good reliability and validity and is considered a gold standard for assessing balance in these populations.
Study: NCT05177302

Intervention type: OTHER
Intervention: HAGOS-C
Description: The subjects will be instructed to complete HAGOS-C at the initial contact and again after 1 week and 4 month for reliability and responsiveness test, respectively

Intervention type: OTHER
Intervention: SF-36v2
Description: The subjects will be instructed to complete SF-36v2 at the initial contact to determine the validity of HAGOS-C
Study: NCT04972110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500 (camonsertib)
Description: RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)
Study: NCT05917392

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Vegetables (Kimchi) supplementation
Description: Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Supplementation with Kimchi plus LGG 50 grams daily for two months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polyphenol
Description: Supplementation with Kimchi plus polyphenol 50 grams daily for two months
Study: NCT04724291

Intervention type: DEVICE
Group type: OTHER
Intervention: MAGNET
Description: This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
Study: NCT06185686

Intervention type: OTHER
Intervention: Cognitive testing
Description: NIH Toolbox Cognitive Battery and the Novel Cognitive Measure (NCM)

Intervention type: DEVICE
Intervention: Resting State MRI/Precision functional mapping
Description: At baseline (before the end of radiation therapy) and approximately 12 months after the completion of radiation therapy.
Study: NCT05817591

Intervention type: OTHER
Intervention: Questionnaires
Description: In current practice, capsaicin patch treatment is offered to patients with a 24-hour average pain level measured by the EN numerical scale : EN scale is \> 4 Pain monitoring questionnaires will be completed by patients every 6 weeks : Neuropathic Pain Symptom Invetory (NPSI Score), Patients' Global Impression of Change (PGIC scale), Numerical pain scale
Study: NCT04935190

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitalpercept
Description: Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitalpercept
Description: Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
Study: NCT04614194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Oral. Tablets should be taken at the same times every day, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Oral. Tablets should be taken at the same times every day, with or without food.
Study: NCT04734600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Treadmill device
Description: group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release technique
Description: group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg
Study: NCT05852561

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Superficial+Deep Serratus Anterior Plan Block
Description: The block will be performed after induction of general anesthesia and surgical positioning. 15 ml of 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and latissimus dorsalis muscles. The same concentration of block fluid will be applied between the serratus anterior and the outer intercostal muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Deep Serratus Anterior Plan Block
Description: 30 ml 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and outer intercostal muscle.
Study: NCT06338124

Intervention type: DIAGNOSTIC_TEST
Intervention: Triglyceride glucose index
Description: To evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome.

Intervention type: DIAGNOSTIC_TEST
Intervention: Triglyceride glucose index
Description: To evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome.